Imagen develops patient-derived cancer cell models (PDCs)
which accelerate drug development
The problem
Global cancer incidence is projected to increase by >62% by 2030 and drug development is too slow and inefficient
- Average time to develop a new cancer drug is >10 years at a cost of >£1bn for each marketed drug
- Only 1 in 10s of thousands of drug candidates makes it to market
The solution
Imagen is targeting cancer by developing a biobank of PDCs and data assets that support the development of new cancer treatments.
- Imagen’s biobank contains the world’s largest collection of predictive patient-derived cancer models (PDCs)
- Imagen’s goal: Make available to biopharma >5,000 PDCs by 2025
- Imagen can rapidly screen thousands of drugs in development on hundreds of PDCs in a more cost-effective way compared to existing approaches
- Screening investigational drugs on Imagen’s PDCs improves go/no-go decision making earlier in development, saving time and money
Main cause
Poor availability of rapid, cost-effective, and predictive cancer models for use during drug development
Main USP
Imagen rapidly screens drugs in development on predictive cancer models in a cost-effective way
| Company locations | Sci-tech Daresbury UK, and Manchester Science Park UK |
| Investment sought | £10m (Q4 2022) carries the company to profitability in 2024 |
| Use of funds | Commercialisation scale-up supporting a UK, US and RoW pipeline Scale-up of UK laboratory team, including expanding Daresbury facility Building in-house genomics capabilities Implementation of an internal R&D program to expand capabilities Expansion of scientific, ops, digital and business development team Progress international medical affairs strategy for tumour acquisition Progress digital infrastructure and AI platform |
| Existing investors | Business supported by private investors to date (c.£11.5m raised) Board members or associates hold 35% of the share capital |
Disclaimer
The content of this communication has not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000. Reliance on this communication for the purpose of engaging in any investment activity may expose an individual to a significant risk of losing all of the property or other assets invested.
Contacts
Dr Laurent Pacheco, Venture Partner, Oyster VP Laurent.pacheco@oystervp.com
Dr Jonathan Engler, Imagen Chair jonathan.engler@imagentherapeutics.com
Mr Geoff Muckle, Imagen CEO geoff.muckle@imagentherapeutics.com
Mrs Nicki Grundy, Imagen CFO nicki.grundy@imagentherapeutics.com